Aromatase inhibitors (AIs) can inactivate aromatase, block aromatase reaction, inhibit estrogen production, and reduce estrogen levels in the blood, being an ideal ET drugs for ER+ BC in postmenopausal women. Here, ESR1 is linked to breast cancer.